Laropiprant

CAS: 571170-77-9

Ref. 3D-FC75279

Produktinformation

• Name: Laropiprant
• Synonyme: (-)-[(3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid, (3R)-4-[(4-Chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)cyclopent[b]indole-3-acetic acid, (R)-2-(4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-[(3R)-4-[(4-Chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid, Cardaptive, Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)-, Mk-0524, [(3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
• CAS: 571170-77-9

Beschreibung

Laropiprant is a drug that is designed to lower the levels of LDL cholesterol in the blood. It has been shown to be effective for long-term use and has metabolic effects with limited side effects. Laropiprant lowers LDL cholesterol by decreasing the production of prostaglandin J2 and increasing the excretion of bile acids, which are produced as a result of increased camp levels. The enzyme responsible for hepatic glucuronidation is inhibited by laropiprant, which leads to increased levels of its active form. Laropiprant also inhibits atherosclerosis through an in vitro method that involves human macrophages.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 435.9 g/mol
• Formel: C₂₁H₁₉ClFNO₄S
• Reinheit: Min. 95%
• Farbe/Form: White Powder
• InChl: InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
• InChI Key: InChIKey=NXFFJDQHYLNEJK-CYBMUJFWSA-N
• SMILES: CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3